Ra Pharmaceuticals (NASDAQ:RARX)‘s stock had its “outperform” rating restated by investment analysts at Credit Suisse Group in a note issued to investors on Thursday. They currently have a $16.00 target price on the stock. Credit Suisse Group’s price target would indicate a potential upside of 100.00% from the company’s previous close.
Several other equities analysts also recently commented on the company. BMO Capital Markets reiterated an “outperform” rating and issued a $34.00 target price (up from $31.00) on shares of Ra Pharmaceuticals in a research report on Monday, December 4th. Royal Bank of Canada reiterated a “buy” rating and issued a $18.00 target price on shares of Ra Pharmaceuticals in a research report on Tuesday, December 5th. Zacks Investment Research downgraded Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 15th. Finally, Jefferies Group reiterated a “buy” rating and issued a $25.00 target price on shares of Ra Pharmaceuticals in a research report on Thursday, September 28th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $20.50.
Shares of Ra Pharmaceuticals (NASDAQ:RARX) traded down $0.18 during mid-day trading on Thursday, hitting $8.00. The company had a trading volume of 122,573 shares, compared to its average volume of 116,349. Ra Pharmaceuticals has a twelve month low of $7.15 and a twelve month high of $27.84.
Institutional investors have recently bought and sold shares of the business. Alliancebernstein L.P. bought a new position in Ra Pharmaceuticals in the second quarter valued at about $195,000. The Manufacturers Life Insurance Company increased its stake in shares of Ra Pharmaceuticals by 30.6% in the second quarter. The Manufacturers Life Insurance Company now owns 10,860 shares of the company’s stock valued at $204,000 after buying an additional 2,543 shares during the period. Rhumbline Advisers acquired a new stake in shares of Ra Pharmaceuticals in the second quarter valued at about $241,000. Swiss National Bank acquired a new stake in shares of Ra Pharmaceuticals in the second quarter valued at about $247,000. Finally, New York State Common Retirement Fund increased its stake in shares of Ra Pharmaceuticals by 87.8% in the second quarter. New York State Common Retirement Fund now owns 13,900 shares of the company’s stock valued at $260,000 after buying an additional 6,499 shares during the period. Hedge funds and other institutional investors own 69.64% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/01/21/credit-suisse-group-reiterates-outperform-rating-for-ra-pharmaceuticals-rarx.html.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.